SUBSCRIBE

Breaking News on Supplements & Nutrition - EuropeUS edition

Headlines > Industry

Is Danone feeling the need for Mead?

Post a comment

By Shane Starling+

28-Jul-2014
Last updated on 30-Jul-2014 at 10:53 GMT

Mead Johnson Nutrition: A Danone target?
Mead Johnson Nutrition: A Danone target?

 Danone shares rose today as rumours strengthened the French dairy giant would sell its medical and paediatric nutrition business (Nutricia), but is the firm streamlining its activities around its core foods businesses or just shifting infant-medical gears?

Media outlets including the Wall Street Journal and The Financial Times reported Danone is in advanced discussions over a potential €3+bn deal for Danone-Nutricia with Illinois-based drug firm Hospira, although previous suitors for the division like Nestlé, Fresenius were not being totally ruled out.

Analysts said Danone, which underperformed in the first half this financial period and has been criticised for losing its innovation edge amid rising raw material costs, slow consumer demand and regulatory upheaval, would use any sales funds to target Mead Johnson Nutrition.

Selling to buy?

Mead may appeal as it is more tightly focused on infant nutrition.

“The question is how Danone would invest the proceeds of a sale,” Patrik Lang from Julius Baer Group told Bloomberg.

“It’s possible a bigger acquisition is imminent – Mead Johnson would be a candidate.”

Mead Johnson Nutrition is estimated to be worth in the vicinity of €14bn and owns infant formula brands such as Enfamil.

Nutricia offerings include Souvenaid (for the elderly) and Nutrini (children).

Danone, which is the world’s largest yoghurt enterprise with mega-brands like Activia and Actimel, was unavailable for comment. Hospira has also not commented on the matter.

Danone Group shares were trading at about €56 today on the Paris stock exchange.

One report suggested Hospira was interested in the deal, in part at least, as it would be able to shift its tax base to France.

Subscribe to our FREE newsletter

Get FREE access to authoritative breaking news, videos, podcasts, webinars and white papers. SUBSCRIBE

Post a comment

Comment title *
Your comment *
Your name *
Your email *

We will not publish your email on the site

I agree to Terms and Conditions

These comments have not been moderated. You are encouraged to participate with comments that are relevant to our news stories. You should not post comments that are abusive, threatening, defamatory, misleading or invasive of privacy. For the full terms and conditions for commenting see clause 7 of our Terms and Conditions ‘Participating in Online Communities’. These terms may be updated from time to time, so please read them before posting a comment. Any comment that violates these terms may be removed in its entirety as we do not edit comments. If you wish to complain about a comment please use the "REPORT ABUSE" button or contact the editors.

Related products